These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 10173098)
1. Laboratory considerations in the rapid determination of drugs in patient specimens. Fuentes-Block L Am Clin Lab; 1997 Jun; 16(5):4, 6. PubMed ID: 10173098 [No Abstract] [Full Text] [Related]
2. Rapid screening and determination of designer drugs in saliva by a nib-assisted paper spray-mass spectrometry and separation technique. Lee H; Jhang CS; Liu JT; Lin CH J Sep Sci; 2012 Oct; 35(20):2822-5. PubMed ID: 22949336 [TBL] [Abstract][Full Text] [Related]
3. Phytosterols and anabolic agents versus designer drugs. De Brabander HF; Verheyden K; Mortier V; Le Bizec B; Verbeke W; Courtheyn D; Noppe H Anal Chim Acta; 2007 Mar; 586(1-2):49-56. PubMed ID: 17386696 [TBL] [Abstract][Full Text] [Related]
4. Drugs in oral fluid Part I. Validation of an analytical procedure for licit and illicit drugs in oral fluid. Wylie FM; Torrance H; Anderson RA; Oliver JS Forensic Sci Int; 2005 Jun; 150(2-3):191-8. PubMed ID: 15944059 [TBL] [Abstract][Full Text] [Related]
5. Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole time-of-flight mass spectrometry identification. Nielen MW; Bovee TF; van Engelen MC; Rutgers P; Hamers AR; van Rhijn JH; Hoogenboom LR Anal Chem; 2006 Jan; 78(2):424-31. PubMed ID: 16408923 [TBL] [Abstract][Full Text] [Related]
6. The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Torrance H; Cooper G Forensic Sci Int; 2010 Oct; 202(1-3):e62-3. PubMed ID: 20685050 [No Abstract] [Full Text] [Related]
7. Drugs in oral fluid Part II. Investigation of drugs in drivers. Wylie FM; Torrance H; Seymour A; Buttress S; Oliver JS Forensic Sci Int; 2005 Jun; 150(2-3):199-204. PubMed ID: 15944060 [TBL] [Abstract][Full Text] [Related]
8. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nishikawa M; Nakajima K; Tsuchihashi H J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(2):315-22. PubMed ID: 15833296 [TBL] [Abstract][Full Text] [Related]
9. Bioanalysis of new designer drugs. Wohlfarth A; Weinmann W Bioanalysis; 2010 May; 2(5):965-79. PubMed ID: 21083227 [TBL] [Abstract][Full Text] [Related]
10. Laboratory issues in the implementation of the marker method. Cowan DA; Bartlett C Growth Horm IGF Res; 2009 Aug; 19(4):357-60. PubMed ID: 19574074 [TBL] [Abstract][Full Text] [Related]
11. Urinary screening for methylphenidate (Ritalin) abuse: a comparison of liquid chromatography-tandem mass spectrometry, gas chromatography-mass spectrometry, and immunoassay methods. Eichhorst J; Etter M; Lepage J; Lehotay DC Clin Biochem; 2004 Mar; 37(3):175-83. PubMed ID: 14972638 [TBL] [Abstract][Full Text] [Related]
12. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. Habrdova V; Peters FT; Theobald DS; Maurer HH J Mass Spectrom; 2005 Jun; 40(6):785-95. PubMed ID: 15827969 [TBL] [Abstract][Full Text] [Related]
13. Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry. Pelander A; Ristimaa J; Rasanen I; Vuori E; Ojanperä I Ther Drug Monit; 2008 Dec; 30(6):717-24. PubMed ID: 18806694 [TBL] [Abstract][Full Text] [Related]
14. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. Ewald AH; Fritschi G; Maurer HH J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 857(1):170-4. PubMed ID: 17632045 [TBL] [Abstract][Full Text] [Related]
15. Product ion mass spectra of amphetamine-type substances, designer analogues, and ketamine using ultra-performance liquid chromatography/tandem mass spectrometry. Apollonio LG; Whittall IR; Pianca DJ; Kyd JM; Maher WA Rapid Commun Mass Spectrom; 2006; 20(15):2259-64. PubMed ID: 16810638 [TBL] [Abstract][Full Text] [Related]
16. Computing a new family of shape descriptors for protein structures. Røgen P; Sinclair R J Chem Inf Comput Sci; 2003; 43(6):1740-7. PubMed ID: 14632419 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of amphetamines and amphetamine-derived designer drugs in human urine by GC-MS. Maresová V; Chadt J; Prikryl L Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():121-4. PubMed ID: 17159795 [TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. Pichini S; Pujadas M; Marchei E; Pellegrini M; Fiz J; Pacifici R; Zuccaro P; Farré M; de la Torre R J Pharm Biomed Anal; 2008 Jun; 47(2):335-42. PubMed ID: 18262381 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, full chemical characterisation and development of validated methods for the quantification of (±)-4'-methylmethcathinone (mephedrone): a new "legal high". Santali EY; Cadogan AK; Daeid NN; Savage KA; Sutcliffe OB J Pharm Biomed Anal; 2011 Sep; 56(2):246-55. PubMed ID: 21680127 [TBL] [Abstract][Full Text] [Related]
20. Quantitative mass spectrometry in biochemistry and medicine. Lehmann WD; Schulten HR Angew Chem Int Ed Engl; 1978 Apr; 17(4):221-38. PubMed ID: 418711 [No Abstract] [Full Text] [Related] [Next] [New Search]